All In Biotech

Drug Trial Radar · NCT00817011

Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness

Phase 4 Study of Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness

Last checked: Nov 19, 2026Latest source record: Dec 31, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

1,000

Planned (sponsor's estimate)

Start

Apr 2006

Primary completion

Dec 2016

Study completion Mar 2018

Sponsor

Lead sponsor
Samsung Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 6, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 25 years, up to 85 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The Purpose of this study is to predict antidepressant response in advance using pharmacogenomics and peripheral biological markers in depressed patients.

Conditions

  • Depression
  • Antidepressant Drug Adverse Reaction

Interventions

  • SSRI treated groupDrug

    Antidepressant administration of SSRI class for 6 weeks under therapeutic dose

  • non-SSRI treated groupDrug

    Antidepressant administration of non-SSRI class for 6 weeks under therapeutic dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. all pharmacogenetic and biological marker variables cause drug responseTime frame: 24weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Samsung Medical Center

    Kangnam, Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.